natureresearch

| Corresponding author(s): | Emmanuel D. Levy | |
|--------------------------|------------------|------------------|
| Initial submission | Revised version | Final submission |

Life Sciences Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.

For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.

| | e de la companya de l | | | | |
|----------|--|---|--|--|--|
| | Experimental design | | | | |
| 1. | Sample size | | | | |
| | Describe how sample size was determined. | Sample size was determined by the available structures in the Protein Data Bank and in the 3DComplex database | | | |
| 2. | Data exclusions | | | | |
| | Describe any data exclusions. | All the available structures were included | | | |
| 3. | Replication | | | | |
| | Describe whether the experimental findings were reliably reproduced. | NA | | | |
| 4. | Randomization | | | | |
| | Describe how samples/organisms/participants were allocated into experimental groups. | NA | | | |
| 5. | Blinding | | | | |
| | Describe whether the investigators were blinded to group allocation during data collection and/or analysis. | NA | | | |
| | Note: all studies involving animals and/or human research partici | pants must disclose whether blinding and randomization were used. | | | |
| 6. | Statistical parameters | | | | |
| | For all figures and tables that use statistical methods, con Methods section if additional space is needed). | firm that the following items are present in relevant figure legends (or in the | | | |
| n/a | Confirmed | | | | |
| | The exact sample size (n) for each experimental group/or | ondition, given as a discrete number and unit of measurement (animals, litters, cultures, etc. | | | |
| \geq | A description of how samples were collected, noting sample was measured repeatedly | whether measurements were taken from distinct samples or whether the same | | | |
| \times | A statement indicating how many times each experiment was replicated | | | | |
| | The statistical test(s) used and whether they are one complex techniques should be described in the Metl | e- or two-sided (note: only common tests should be described solely by name; more nods section) | | | |
| \geq | A description of any assumptions or corrections, suc | h as an adjustment for multiple comparisons | | | |
| | The test results (e.g. P values) given as exact values V | whenever possible and with confidence intervals noted | | | |
| | A clear description of statistics including central tend | dency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range) | | | |
| | Clearly defined array bars | | | | |

See the web collection on statistics for biologists for further resources and guidance.

Software

Policy information about availability of computer code

7. Software

Describe the software used to analyze the data in this studv.

Data analyses were carried out with custom Perl and R scripts. The core engine of the work for structural superposition of quaternary structures is available on Github. The predictions resulting from the method are available at www.QSbio.org

For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.

| | M | ateri | als | and | rea | gents |
|-----|-----|-------|-----|-----|------|--------|
| , , | V I | accii | uij | unu | 1 Cu | SCIICO |

8. Materials availability

Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.

| N/A | | | |
|-----|--|--|--|
| | | | |
| | | | |

9. Antibodies

Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).

| N/A | | | |
|-----|--|--|--|
| | | | |

10. Eukaryotic cell lines

- a. State the source of each eukaryotic cell line used.
- N/A
- b. Describe the method of cell line authentication used.
- N/A N/A
- c. Report whether the cell lines were tested for mycoplasma contamination.
- N/A
- d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by
- ICLAC, provide a scientific rationale for their use.

▶ Animals and human research participants

Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines

11. Description of research animals

Provide details on animals and/or animal-derived materials used in the study.

| I/A | | | |
|-----|--|--|--|
| | | | |

Policy information about studies involving human research participants

12. Description of human research participants

Describe the covariate-relevant population characteristics of the human research participants.

| N/A | | | |
|-----|--|--|--|
| | | | |